AGN - Tiziana Life Sciences Plans To Raise $16 Million In U.S. IPO
Quick Take
Tiziana Life Sciences plc (TLSA) is seeking to raise $16 million in a U.S. IPO, according to an amended registration statement.
The company is advancing a pipeline of therapeutic candidates for various cancers and immune diseases.
TLSA is developing promising treatments with large and rapidly growing markets, but the firm faces significant competition.
Company & Technology
Mayfair, UK-based biotechnology company Tiziana Life Sciences was founded in 2013 to develop new molecules to treat oncology and immunology diseases.
Management is headed by Chief Scientific Officer (CSO), Executive Director and CEO Kunwar